Evidence map›Paper›PMID 38729265›Full record

ReviewAdvanced drug delivery reviews2024

Engineering antigen-presenting cells for immunotherapy of autoimmunity.

Clinton T Smith, Zhenyu Wang, Jamal S Lewis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Clinton T SmithJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
Zhenyu WangJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.
Jamal S LewisJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA; Department of Biomedical Engineering, University of California, Davis, CA 95616, USA. Electronic address: jlewis@bme.ufl.edu.

Funding

Particulate-based in vivo modulation for immunotherapy of Rheumatoid ArthritisR01AI139399 · NIAID · UNIVERSITY OF FLORIDA · PI LEWIS, JAMAL S · 2019 to 2023
$1.9M
SUGAR-COATING HYPOALLERGENS - A NOVEL APPROACH FOR SHELLFISH ALLLERGY IMMUNOTHERAPYR03AI138191 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEWIS, JAMAL S · 2019 to 2020
$151k
NIAID NIH HHS R01 AI139399NIAID NIH HHS R03 AI138191
6 · The paper itself

Abstract

Autoimmune diseases are burdensome conditions that affect a significant fraction of the global population. The hallmark of autoimmune disease is a host's immune system being licensed to attack its tissues based on specific antigens. There are no cures for autoimmune diseases. The current clinical standard for treating autoimmune diseases is the administration of immunosuppressants, which weaken the immune system and reduce auto-inflammatory responses. However, people living with autoimmune diseases are subject to toxicity, fail to mount a sufficient immune response to protect against pathogens, and are more likely to develop infections. Therefore, there is a concerted effort to develop more effective means of targeting immunomodulatory therapies to antigen-presenting cells, which are involved in modulating the immune responses to specific antigens. In this review, we highlight approaches that are currently in development to target antigen-presenting cells and improve therapeutic outcomes in autoimmune diseases.

Indexed as

Antigen-Presenting CellsAutoimmune DiseasesAutoimmunityImmunotherapyAnimalsHumansAntigen-presenting cellsAutoimmunityBiomaterialsDrug deliveryImmunomodulation

Identifiers

PMID38729265
PMCPMC13476868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.